Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial.

被引：0

作者：

Fountzilas, Christos

Liao, Chih-Yi

Pelster, Meredith

Li, Daneng

Deming, Dustin A.

Sahai, Vaibhav

Kankeu Fonkoua, Lionel Aurelien

Cohn, Allen Lee

Mantry, Parvez

Richards, Donald A.

Kingsley, Ed

Wu, Frank

Peng, Peng

Hennessy, Katie

Wang, Hui

Shan, Yujun

Sun, Caixia

Fan, Jean

Javle, Milind M.

Mahipal, Amit

机构：

[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[2] Univ Chicago, Med Ctr, Chicago, IL USA

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA

[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[6] Univ Michigan, Ann Arbor, MI USA

[7] Mayo Clin Rochester, Dept Med Oncol, Rochester, MN USA

[8] Rocky Mt Canc Ctr, Denver, CO USA

[9] Liver Inst Methodist Dallas, Dallas, TX USA

[10] Texas Oncol Tyler, Tyler, TX USA

[11] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[12] TransThera Sci Nanjing Inc, Nanjing, Peoples R China

[13] TransThera Sci US Inc, Gaithersburg, MD USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[15] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Cleveland Hts, OH USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.608

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

608

引用

页码：608 / 608

页数：1

共 50 条

[31] A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report
Sohal, Davendra
Teitelbaum, Ursina R.
Uehara, Takeshi
Mykulowycz, Kristine
Watt, Christopher D.
Damjanov, Nevena
Giantonio, Bruce J.
Carberry, Mary
Wissel, Paul Stephen
Jacobs-Small, Mona
O'Dwyer, Peter J.
Sepulveda, Antonia
Sun, Weijing
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[32] Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
Tabernero, J.
Shitara, K.
Dvorkin, M.
Mansoor, W.
Arkenau, H. T.
Prokharau, A.
Alsina, M.
Ghidini, M.
Faustino, C.
Gorbunova, V.
Zhavrid, E.
Nishikawa, K.
Hosokawa, A.
Ganea, D.
Yalcin, S.
Fujitani, K.
Beretta, G.
Winkler, R.
Makris, L.
Doi, T.
Ilson, D.
ANNALS OF ONCOLOGY, 2018, 29 : 122 - 122
[33] Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.
Porcu, Pierluigi
Bagot, Martine
Ram-Wolff, Caroline
Kim, Youn H.
Huen, Auris
Dalle, Stephane
Poligone, Brian
Mehta-Shah, Neha
Modeste, Anne Benedicte Duval
Zinzani, Pier Luigi
Woei-A-Jin, Feng Jung Sherida Harriette
Eigentler, Thomas
Combalia, Andrea
Sokol, Lubomir
Battistella, Maxime
Gru, Alejandro
Teisserenc, Helene Moins
Viotti, Julien
Paiva, Christine
Chammard, Agnes Boyer
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[34] Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial
Bagot, Martine
Kim, Youn H.
Ortiz-Romero, Pablo L.
Zinzani, Pier Luigi
Mehta-Shah, Neha
Dereure, Olivier
Beylot-Barry, Marie
Dalle, Stephane
Jacobsen, Eric D.
Huen, Auris
Combalia, Andrea
Battistella, Maxime
Gru, Alejandro A.
Moins-Teisserenc, Helene
Khodadoust, Michael S.
Viotti, Julien
Paiva, Christine
Muller, Marianna
Porcu, Pierluigi
BLOOD, 2022, 140 : 3760 - 3761
[35] Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS)
Yamamoto, Yutaka
Iwata, Hiroji
Takahashi, Masato
Yoshinami, Tetsuhiro
Ueno, Takayuki
Toyama, Tatsuya
Yamanaka, Takashi
Takano, Toshimi
Kashiwaba, Masahiro
Tsugawa, Koichiro
Hasegawa, Yoshie
Tamura, Kenji
Tada, Hiroshi
Hara, Fumikata
Taira, Naruto
Saji, Shigehira
Morita, Satoshi
Toi, Masakazu
Ohno, Shinji
Masuda, Norikazu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival
Ahlborn, M.
Lordick, F.
ONKOLOGE, 2014, 20 (04): : 376 - 377
[37] Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival
Troeger, W.
Galun, D.
Reif, M.
Schumann, A.
Stankovic, N.
Milicevic, M.
EUROPEAN JOURNAL OF CANCER, 2013, 49 (18) : 3788 - 3797
[38] Overall survival (OS) results from the phase III PHENIX trial of HER2+metastatic breast cancer treated with pyrotinib plus capecitabine
Jiang, Zefei
Yan, Min
Bian, Li
Wang, Tao
Hu, Xichun
Zhang, Qingyuan
Ouyang, Quchang
Feng, Jifeng
Yin, Yongmei
Sun, Tao
Tong, Zhongsheng
Wang, Xiaojia
Yao, Herui
Jiang, Shuping
Zhu, Xiaoyu
Zou, Jianjun
CANCER RESEARCH, 2022, 82 (04)
[39] Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
Tomita, Yoshihiko
Shinohara, Nobuo
Yuasa, Takeshi
Fujimoto, Hiroyuki
Niwakawa, Masashi
Mugiya, Soichi
Miki, Tsuneharu
Uemura, Hirotsugu
Nonomura, Norio
Takahashi, Masayuki
Hasegawa, Yoshihiro
Agata, Naoki
Houk, Brett
Naito, Seiji
Akaza, Hideyuki
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (12) : 1166 - 1172
[40] Clinical downstaging and quality of life after neoadjuvant chemotherapy in patients with locally advanced rectal cancer: Interim analysis from a phase II clinical trial.
Abdalla, Ahmed
Aref, Amr M.
Alame, Amer
Ma, Danny
Barawi, Mohammed
Szpunar, Susan
Lambert, Karrah
Kafri, Zyad
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →